Quince Therapeutics Seeks Stockholder Approval for Massive Dilution and Change of Control
QNCX sits 54% above its 52-week low of $15.1.
Summary
Quince Therapeutics filed a preliminary proxy for a special meeting to approve the conversion of preferred stock and warrants that would issue up to 16.6 million shares, diluting existing holders by over 90%, and to approve a change of control that installs Orphai Therapeutics' management.
Key Events · Corporate Governance and Compliance · QNCX
-
Massive Dilution Vote
Stockholders will vote on the conversion of Series C Preferred Stock and exercise of warrants and options that would issue up to 16,615,932 shares of common stock, representing approximately 94.23% of the shares outstanding as of the record date.
-
Change of Control
Approval triggers the resignation of CEO Dirk Thye and COO Brendan Hannah, with Orphai Therapeutics executives Brigette Roberts (CEO), John Militello (CFO), and Keith Fandrick (COO) taking over.
-
Cash Settlement Risk
If stockholder approval is not obtained by November 18, 2026, holders of Series C Preferred Stock can require the company to cash-settle their shares at fair value, a potentially severe cash drain.
-
Authorized Share Increase
Proposal to increase authorized common stock from 250 million to 275 million shares to accommodate the conversion and future equity needs.
Analysis · QNCX · Life Sciences
Quince Therapeutics is asking stockholders to approve the conversion of Series C Preferred Stock and exercise of warrants and options that would flood the market with up to 16.6 million new shares — roughly 94% of the current outstanding. The vote also triggers a change of control: the CEO and COO resign, and Orphai Therapeutics executives take over. If stockholders don't approve by November 18, 2026, the company could be forced to cash-settle the preferred stock, a potentially crippling cash outflow. This is the final step in the reverse merger with Orphai, and the outcome will determine whether existing shareholders are massively diluted or the company faces a cash crisis.
At the time of this filing, QNCX was trading at $23.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.9M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.